Clinical Trial Update: Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan [Phase 3]

View source ↗

Summary

Sanofi Pasteur's SP059 poliovirus vaccine candidate was studied in a three-dose primary plus booster schedule in infants in Japan, and the Phase 3 trial has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• SP059 (SP059)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Poliomyelitis, Polio | Phase 3 | Status: COMPLETED